tiprankstipranks

Kevin Charles Gorman Insider Profile

4 Followers
Kevin Charles Gorman, CEO, Director at Neurocrine, holds 514.60K shares in Neurocrine (Ticker: NBIX), holds 5.06K shares in Xencor (Ticker: XNCR).
tipranks
Kevin Charles Gorman

Kevin Charles Gorman
Neurocrine (NBIX)
CEO, Director

Ranked #20,328 out of 98,564 Corporate Insiders

Profitable Transactions

60%
3 out of 5 Profitable Transactions

Average Return

+14.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$69M
99.87%
0.13%
A breakdown of Kevin Charles Gorman's holdings

Insider Roles

Neurocrine
(NBIX)
CEO, Director
Xencor
(XNCR)
Director
Roles that Kevin Charles Gorman holds in companies

Most Profitable Insider Trade

Stock:
Neurocrine
(NBIX)
Rating:Informative Buy
Date:Dec 23, 2016 - Dec 23, 2017
Return:+81.10%
The most profitable trade made by Kevin Charles Gorman

Kevin Charles Gorman's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Neurocrine
Feb 15, 2024
CEO, Director
Uninformative Sell
376.68K
$68.78M
Xencor
Feb 15, 2024
Director
Informative Buy
1.01K
$92.14K
List of latest transactions for each holding click on a transaction to see Kevin Charles Gorman's performance on stock

Kevin Charles Gorman insider profile FAQ

What is the percentage of profitable transactions made by Kevin Charles Gorman?
The percentage of profitable transactions made by Kevin Charles Gorman is 60%.
    What is the average return per transaction made by Kevin Charles Gorman?
    The average return per transaction made by Kevin Charles Gorman is 14.90%.
      What stocks does Kevin Charles Gorman hold?
      Kevin Charles Gorman holds: NBIX, XNCR stocks.
        What was Kevin Charles Gorman’s latest transaction?
        Kevin Charles Gorman latest transaction was an Uninformative Sell of $376.68K.
          What was Kevin Charles Gorman's most profitable transaction?
          Kevin Charles Gorman’s most profitable transaction was an Informative Buy of NBIX stock on December 23, 2016. The return on the trade was 81.10%.
            What is Kevin Charles Gorman's role in Neurocrine?
            Kevin Charles Gorman's role in Neurocrine is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.